Agilisium earns AWS Life Sciences Competency Status, joining elite group of 28 global partners

New Delhi: Agilisium has achieved the esteemed AWS Life Sciences Competency status, placing it among an exclusive group of 28 Consulting Partners out of over 8,300 AWS Partners globally.

This recognition highlights Agilisium’s expertise in providing transformative cloud solutions for pharmaceutical companies, aiding in expediting drug discovery, enhancing clinical trials, and developing new genetic-based treatments.

Agilisium has developed more than 20 GenAI-powered data analytics solutions, showcasing its innovative approach to enabling pharmaceutical organizations to gain deeper insights and accelerate research and development processes. These solutions and accelerators are available through the AWS marketplace, making advanced analytics accessible to a wider audience.

Raj Babu, Founder and CEO of Agilisium, expressed, “Earning the AWS Life Sciences Competency status is a significant milestone for Agilisium. This achievement reflects our team’s unwavering dedication to understanding the complex challenges in the pharma industry and developing solutions that effectively address them. By harnessing the power of our GenAI solutions, we are confident that we can usher in a new era of data-driven discovery and innovation in life sciences. Additionally, this recognition would enable our clients to transform data into meaningful insights, ultimately delivering life-changing therapies to patients faster, globally.”

As one of the few AWS-certified Data Analytics partners with specialized expertise in the pharmaceutical industry, Agilisium offers a broad range of AWS services tailored for the Life Sciences sector. These services include generative AI solutions, advanced analytics, data lakes, and machine learning. Additionally, the company provides AWS’s Migration Acceleration Program (MAP) funding and No-Cost Assessment programs to help clients accelerate their cloud transformation journeys.